Novel lysin-based antibacterial agent could help combat MRSA
Researchers have engineered F12, a lysin-based antibacterial drug, to have limited negative side-effects and so it can be administered repeatedly without loss of efficacy.
List view / Grid view
Researchers have engineered F12, a lysin-based antibacterial drug, to have limited negative side-effects and so it can be administered repeatedly without loss of efficacy.
A computational programme has been created by researchers to aid in the design of proteins for therapeutics, to predict interactions.
Researchers have developed a technique to produce synthetic steroids that could pave the way for a cascade of new drug discoveries...
3 March 2016 | By Victoria White
According to the research, a drug for a disease that affects twice as many people will generate twice the revenue. But vaccine revenue depends on finer details about how the risk is distributed in the population...
22 January 2016 | By Victoria White
Dartmouth researchers have discovered that one of their recently discovered chemical reactions is capable of delivering some of the most potent and rare neurotrophins...